Asunaprevir (BMS-650032): A Comprehensive Monograph on a Second-Generation HCV NS3/4A Protease Inhibitor

Executive Summary

Asunaprevir is a potent, second-generation, direct-acting antiviral (DAA) agent that functions as a selective inhibitor of the Hepatitis C Virus (HCV) nonstructural protein 3/4A (NS3/4A) protease.[1] Developed by Bristol-Myers Squibb under the code BMS-650032, it represents a significant milestone in the therapeutic evolution for chronic hepatitis C. Asunaprevir's primary contribution to medicine was its role as a key component in some of the first all-oral, interferon-free treatment regimens, most notably in a dual-combination therapy with the NS5A replication complex inhibitor, daclatasvir.[4] This combination marked a paradigm shift, moving away from the poorly tolerated and less effective interferon-based therapies and demonstrating that a virologic cure could be achieved with well-tolerated oral medications.

Clinically, Asunaprevir-based regimens have demonstrated high efficacy, particularly against HCV genotypes 1b and 4, achieving sustained virologic response (SVR) rates in the range of 80% to 90% in both treatment-naïve and treatment-experienced patient populations.[1] This success, however, is juxtaposed with two significant clinical liabilities that have defined its therapeutic niche and global regulatory trajectory. The first is a considerable risk of hepatotoxicity, manifesting as elevated liver transaminases, which was observed to be more frequent and severe in certain populations, notably patients of Asian descent.[8] This safety concern was the principal reason for the withdrawal of its New Drug Application (NDA) in the United States.[8] The second limitation is a low genetic barrier to viral resistance, with the rapid emergence of resistance-associated substitutions at key positions in the NS3 protease, necessitating its strict use in combination with other DAAs acting on different viral targets.[4]

This complex risk-benefit profile has resulted in a divergent global regulatory history. Asunaprevir was approved for clinical use in several countries, including Japan, Russia, and China, where it is marketed under the brand name Sunvepra®.[5] In these regions, it addressed a significant unmet need, particularly for the highly prevalent genotype 1b. Conversely, it failed to gain approval in the United States and the European Union for adult treatment. Asunaprevir's journey from a triumph of rational drug design—successfully engineering out the cardiovascular toxicities of its predecessor—to a clinically useful but ultimately niche therapeutic provides a compelling case study in the intricate balance of efficacy, safety, population-specific pharmacokinetics, and the rapidly evolving competitive landscape of modern drug development.

Chemical Identity and Physicochemical Properties

A comprehensive understanding of a pharmaceutical agent begins with its precise chemical identity and physical characteristics, which dictate its formulation, delivery, and interaction with biological systems. This section details the nomenclature, structural features, and physicochemical properties of Asunaprevir.

Nomenclature and Identifiers

Asunaprevir is identified by a variety of names and registry numbers across scientific literature, regulatory databases, and commercial contexts, ensuring its unambiguous identification. Its international non-proprietary name is Asunaprevir.[1] During its development by Bristol-Myers Squibb, it was referred to by the investigational code BMS-650032.[1] Upon receiving marketing authorization in select countries, it was commercialized under the brand name Sunvepra, notably in Japan and Russia.[11]

The definitive chemical name, according to the International Union of Pure and Applied Chemistry (IUPAC) nomenclature, is tert-butyl N-carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate.[1] This complex name reflects its structure as a tripeptidic acylsulfonamide derivative.[16]

For precise database tracking and regulatory filing, Asunaprevir is assigned several unique identifiers. Its primary Chemical Abstracts Service (CAS) Registry Number is 630420-16-5.[1] Other key identifiers are catalogued in Table 1, providing a comprehensive reference for the compound.

Molecular and Structural Characteristics

Asunaprevir is a small molecule drug with the molecular formula C35​H46​ClN5​O9​S and a precise molar mass of 748.29 g·mol−1.[11] Its complex structure is the result of an extensive medicinal chemistry program designed to optimize potency, selectivity, and pharmacokinetic properties while minimizing off-target toxicities.

The molecular architecture of Asunaprevir is a direct testament to a rational drug design campaign aimed at mitigating specific preclinical liabilities. Analysis of its structure reveals that the 7-chloro-isoquinoline moiety was not an arbitrary choice but a critical modification engineered to eliminate the cardiovascular toxicities observed in its predecessor, BMS-605339.[6] The earlier compound was discontinued from clinical trials due to safety concerns including mild bradycardia and PR interval prolongation.[6] Structure-activity relationship studies established that minor structural edits to the P2* subsite of the molecule, which includes the isoquinoline ring, had a profound impact on the cardiovascular safety profile.[6] The selection of the 7-chloro substitution pattern on the isoquinoline ring successfully resolved this liability, producing a compound with a benign profile in preclinical cardiac safety models, thereby enabling its advancement into Phase III clinical trials.[6] This direct linkage between a specific structural feature and the resolution of a dose-limiting toxicity underscores the precision of the underlying drug discovery process.

To facilitate computational modeling and cheminformatic analysis, the structure of Asunaprevir is represented by standardized line notations, including the Simplified Molecular Input Line Entry System (SMILES) and the International Chemical Identifier (InChI) and its hashed version, the InChIKey. These are detailed in Table 1.

Physical, Formulation, and Storage Properties

Asunaprevir exists as a white to yellow solid at room temperature.[15] A critical determinant of its biopharmaceutical behavior is its solubility profile. It exhibits good solubility in various organic solvents, including dimethyl sulfoxide (DMSO) at 10 mM or 25 mg/mL, dimethylformamide (DMF) at 30 mg/mL, and ethanol at 15 mg/mL.[17] However, it is characterized by very poor aqueous solubility, with reported values of less than 50 mg/L.[1]

This poor aqueous solubility presented a significant challenge for oral drug delivery and led to the observation of a "large food effect" with early formulations, where the presence of food in the gastrointestinal tract would have unpredictably altered drug absorption.[16] Such variability is clinically undesirable as it can lead to inconsistent drug exposure and therapeutic response. The formulation of Asunaprevir as a soft-gel capsule was, therefore, not merely a delivery choice but a critical enabling technology for the drug's clinical viability. The soft-gel capsule contains a solution of Asunaprevir in a lipid-based vehicle, including medium-chain triglycerides, caprylic/capric glycerides, and polysorbate 80.[3] This formulation strategy is designed to enhance the dissolution and absorption of lipophilic, poorly soluble compounds. Its implementation successfully "mitigated" the food effect, allowing for more consistent and predictable absorption and enabling flexible dosing with or without food, a significant advantage for patient adherence.[1] This demonstrates a crucial synergy between medicinal chemistry, which produced the active molecule, and pharmaceutical science, which developed the delivery system necessary to make it a reliable therapeutic agent.

For long-term preservation of its chemical integrity, Asunaprevir should be stored at -20 °C, under which conditions it is stable for at least four years.[15] For the purposes of transport, it can be shipped at ambient room temperature.[15]

Table 1: Summary of Asunaprevir Identification and Physicochemical Properties

Parameter	Value	Source Snippet(s)
Generic Name	Asunaprevir	1
Brand Name(s)	Sunvepra	1
Development Code	BMS-650032	1
DrugBank ID	DB11586	1
CAS Number	630420-16-5	1
IUPAC Name	tert-butyl N-carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate	1
Molecular Formula	C35​H46​ClN5​O9​S	11
Molar Mass	748.29 g·mol−1	11
InChIKey	XRWSZZJLZRKHHD-WVWIJVSJSA-N	1
SMILES	CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C	1
Appearance	White to Yellow Solid	15
Solubility (DMSO)	10 mM / 25 mg/mL	17
Solubility (DMF)	30 mg/mL	21
Solubility (Ethanol)	15 mg/mL	21
Solubility (Water)	<50 mg/L	1
Storage Temperature	-20 °C	15
Stability	≥ 4 years (at -20 °C)	21

Mechanism of Action and Virological Profile

Asunaprevir belongs to the class of direct-acting antiviral (DAA) agents, which revolutionized the treatment of chronic hepatitis C by targeting specific viral proteins essential for replication. Its therapeutic effect is derived from a highly specific and potent interaction with a key viral enzyme.

Primary Mechanism of Action

The primary mechanism of action of Asunaprevir is the potent and selective inhibition of the Hepatitis C Virus (HCV) NS3/4A serine protease.[1] The HCV genome is translated into a single large polyprotein, which must be cleaved into individual structural and nonstructural proteins to become functional.[4] The NS3/4A protease, a complex of the NS3 serine protease and its NS4A protein cofactor, is responsible for performing several of these critical proteolytic cleavages, making it absolutely essential for the maturation of viral proteins and the subsequent assembly of new, infectious virions.[2]

Asunaprevir functions as a competitive inhibitor, binding with high affinity to the active site of the NS3 protease.[1] This binding physically obstructs the enzyme's access to its natural polyprotein substrate, thereby preventing the processing of the viral polyprotein and halting the viral replication cycle.[1] The potency of this interaction is quantified by its very low nanomolar half maximal inhibitory concentration (

IC50​) values against the enzyme and its equilibrium inhibition constants (Ki​) of 0.4 nM and 0.24 nM, demonstrating a high-affinity binding interaction.[18] This targeted disruption of a vital step in viral maturation results in a robust antiviral effect and a rapid decline in viral load in treated patients.[4]

Genotypic Specificity and Potency

The antiviral activity of Asunaprevir is not uniform across all HCV genotypes. Its therapeutic utility is largely defined by its spectrum of potent activity. In both biochemical assays measuring direct enzyme inhibition and cell-based HCV replicon assays measuring inhibition of viral replication, Asunaprevir demonstrates the highest potency against HCV genotypes 1 (subtypes 1a and 1b), 4, 5, and 6.[3] For these genotypes, its

IC50​ and half maximal effective concentration (EC50​) values are consistently in the low single-digit nanomolar range. For instance, reported IC50​ values against the NS3/4A protease complex are 0.3 nM for genotype 1b and 1.6 nM for genotype 4a, while EC50​ values in replicon systems are 1.2 nM for genotype 1b and 4 nM for genotype 1a.[3]

In stark contrast, Asunaprevir exhibits significantly weaker activity against HCV genotypes 2 and 3. The EC50​ values for these genotypes are substantially higher, ranging from 67 nM to 1,162 nM, indicating much lower potency.[7] This genotype-specific activity profile is a primary determinant of its approved clinical indications, which are restricted to genotypes 1 and 4.[1]

Furthermore, Asunaprevir is highly selective for its viral target. It shows no meaningful activity against closely related viruses and has been tested against a panel of 11 human serine and cysteine proteases, where its IC50​ values were greater than 5 µM, demonstrating a wide therapeutic window between its antiviral potency and any potential off-target inhibition of host enzymes.[4]

Synergistic Antiviral Activity

Modern antiviral therapy, particularly for rapidly mutating RNA viruses like HCV, relies on combination treatment to maximize efficacy and suppress the emergence of resistance. Asunaprevir was developed and is indicated exclusively for use as part of a combination regimen.[25] In vitro combination studies have consistently demonstrated that Asunaprevir exerts additive and/or synergistic antiviral effects when co-administered with other anti-HCV agents that have different mechanisms of action.[3]

Specifically, synergistic or additive activity has been shown with interferon alfa, various inhibitors of the HCV NS5B polymerase, and, most importantly, the NS5A replication complex inhibitor daclatasvir.[3] The dual-combination regimen of Asunaprevir and daclatasvir targets two distinct and essential components of the viral replication machinery, leading to a profound and sustained suppression of viral replication. This combination forms the basis of its primary clinical application and was shown to produce very high rates of virologic cure.[1] Critically, no antagonism has been observed with any of the antiviral drugs tested, confirming its suitability as a component of multi-drug regimens.[4]

Viral Resistance Profile

A significant clinical limitation of Asunaprevir, shared with other first- and second-generation HCV protease inhibitors, is its low genetic barrier to resistance.[4] The high replication rate and error-prone nature of the HCV RNA-dependent RNA polymerase lead to the continuous generation of viral variants. Under the strong selective pressure exerted by a potent inhibitor like Asunaprevir, pre-existing or newly arising viral strains with mutations in the NS3 protease gene that reduce drug susceptibility are rapidly selected for and can become the dominant viral population, leading to treatment failure.[3]

This dynamic creates a "double-edged sword" that has defined both the clinical utility and the ultimate limitations of Asunaprevir. The high potency of the drug against its target, the NS3 protease, was the very quality that enabled the development of highly effective interferon-free regimens—a revolutionary advance in therapy.[3] However, this same potent and targeted pressure on a single viral enzyme with a high intrinsic mutation rate is what drives the rapid selection of resistant mutants. The emergence of specific resistance-associated substitutions (RASs) is the virus's evolutionary escape from this pressure. This direct relationship between high selective pressure and the rapid selection of resistant variants explains why monotherapy is ineffective and strictly contraindicated, and it foreshadowed the broader need for next-generation, pangenotypic inhibitors with higher barriers to resistance.

In both cell culture selection experiments and in patients who experience virologic failure, a consistent pattern of RASs emerges. The most common and clinically significant substitutions are located at amino acid positions R155 (e.g., R155K) and D168 (e.g., D168A, D168G, D168V, D168Y) within the NS3 protease domain.[3] The presence of these mutations can reduce Asunaprevir's susceptibility by 5-fold to over 280-fold, rendering the drug ineffective.[3]

The structural basis for this pronounced susceptibility to resistance has been elucidated through X-ray crystallography. These studies reveal a key vulnerability in Asunaprevir's binding mode. The P2* isoquinoline moiety of the inhibitor forms a crucial aromatic stacking interaction with the side chain of the arginine residue at position 155 (Arg155) of the protease.[10] The precise orientation of this Arg155 residue is, in turn, stabilized by a salt bridge interaction with the aspartate residue at position 168 (Asp168).[10] This creates a finely tuned electrostatic network that is essential for the high-affinity binding of Asunaprevir. A mutation at either R155 or D168 disrupts this entire network, triggering a "domino-like effect" that compromises the inhibitor's binding and leads to a dramatic loss of potency.[10] This provides a precise molecular explanation for the clinical resistance data and highlights a structural weakness that subsequent drug design efforts, such as the use of macrocyclic inhibitors to pre-organize the inhibitor's conformation, have sought to overcome.[10] The low barrier to resistance is the primary reason why Asunaprevir must always be used in combination with other DAAs that target different viral proteins, such as an NS5A or NS5B inhibitor, to provide multiple, independent hurdles to viral escape.[4]

Pharmacokinetics and Metabolism

The pharmacokinetic profile of a drug describes its absorption, distribution, metabolism, and excretion (ADME), which collectively determine the concentration of the drug at its site of action over time. Asunaprevir exhibits a complex pharmacokinetic profile characterized by rapid absorption, highly preferential liver distribution, extensive metabolism, and specific population-based variability.

Absorption

Following oral administration of the commercial soft-gel capsule formulation, Asunaprevir is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations (Cmax​) are typically reached within a time frame (Tmax​) of 2 to 4 hours post-dose.[2] Pharmacokinetic studies have shown that its exposure, as measured by

Cmax​ and the area under the concentration-time curve (AUC), increases in a dose-proportional manner.[12] With twice-daily dosing, steady-state plasma concentrations are achieved by day 7.[16]

The absolute oral bioavailability of Asunaprevir is reported to be relatively low at 9.3%.[12] This is not uncommon for large, complex, and poorly water-soluble molecules. As discussed previously, the development of the soft-gel capsule was a critical step to overcome biopharmaceutical challenges, particularly by mitigating a large food effect that was observed with earlier formulations and allowing for consistent absorption regardless of meals.[1]

Distribution

The distribution of Asunaprevir in the body is one of its most defining pharmacokinetic characteristics. In systemic circulation, it is extensively bound to plasma proteins, with a bound fraction exceeding 99%.[1] This high degree of protein binding tends to confine the drug to the vascular compartment within the plasma.

However, the most significant feature of its distribution is its highly preferential accumulation in the liver, its primary site of action and metabolism. This phenomenon, known as hepatotropic disposition, is not a passive process but is actively mediated by uptake transporters on the surface of hepatocytes, specifically the organic anion-transporting polypeptides OATP1B1 and OATP2B1.[1] This active transport mechanism results in markedly higher drug concentrations in the liver compared to the plasma. Preclinical studies across multiple species have reported liver-to-plasma concentration ratios ranging from 40 to 359.[4] This targeted distribution is pharmacologically advantageous, as it concentrates the drug at the site of HCV replication, allowing for potent antiviral activity even with relatively low systemic plasma concentrations.[16]

This hepatotropic distribution is a key driver of both the drug's efficacy and its primary toxicity. While the OATP-mediated active transport into hepatocytes is a highly desirable property for concentrating the drug at its target, this same mechanism leads to very high intracellular drug concentrations. It is plausible that this accumulation in hepatocytes, particularly in susceptible individuals or those with higher systemic exposure, contributes directly to the observed risk of hepatotoxicity. The liver is not merely a site of clearance for Asunaprevir; it is a site of active accumulation, which may reach toxic levels and precipitate drug-induced liver injury. This establishes a direct mechanistic link between a favorable pharmacokinetic property (target-site concentration) and the drug's principal safety liability (organ-specific toxicity).

Metabolism

Asunaprevir undergoes extensive hepatic metabolism prior to its elimination from the body. In vitro studies using human liver microsomes and recombinant enzymes have definitively identified the cytochrome P450 (CYP) enzyme CYP3A4 as the primary mediator of its oxidative metabolism.[2] The metabolic pathways are complex and result in the formation of several metabolites through processes that include mono- and bis-oxidation, N-dealkylation, O-demethylation, and cleavage of the isoquinoline ring from the parent molecule.[12]

A notable and clinically relevant feature of Asunaprevir's metabolism is its capacity for auto-induction. Population pharmacokinetic (PopPK) modeling, which analyzes data from a large number of patients, has revealed that the apparent clearance of Asunaprevir increases over the first few days of therapy.[27] Specifically, the typical clearance value of 50.8 L/h at the start of treatment increases by 43% to a steady-state value of 72.5 L/h after approximately two days.[27] This increase is likely due to Asunaprevir inducing the expression of the CYP3A4 enzyme that is responsible for its own metabolism.[27]

Excretion

Consistent with its extensive hepatic metabolism, the primary route of elimination for Asunaprevir and its metabolites is through the feces, which occurs following biliary excretion.[4] Renal elimination of the parent drug is minimal.[16] This route of elimination has important clinical implications, as it means that the drug's clearance is not significantly affected by renal function. Consequently, no dose adjustment is required for patients with any degree of renal impairment, including those with end-stage renal disease requiring hemodialysis.[7]

Population Pharmacokinetics and Special Populations

The disposition of Asunaprevir can be significantly influenced by various intrinsic patient factors, leading to inter-individual variability in drug exposure. Population pharmacokinetic analyses have identified several key covariates that impact its concentration profile.[27]

• Hepatic Impairment: As a drug that is almost exclusively cleared by the liver, the functional state of the liver is the most critical determinant of Asunaprevir exposure. Patients with compensated cirrhosis (Child-Pugh A) have been found to have an 84% increase in AUC compared to those without cirrhosis.[27] Similarly, patients with a baseline aspartate aminotransferase (AST) level above 78 IU/L experience a 58% increase in AUC.[27] The effect is dramatically more pronounced in patients with more severe liver disease. Compared to healthy subjects, patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment exhibit 9.8-fold and 32.1-fold higher AUCs, respectively.[7] This profound increase in exposure is associated with an unacceptable risk of toxicity, leading to the contraindication of Asunaprevir in patients with Child-Pugh B or C cirrhosis or any form of decompensated liver disease.[25]
• Race and Ethnicity: A clinically significant finding from PopPK modeling is the influence of race on Asunaprevir exposure. Asian subjects were found to have a 46% higher steady-state AUC compared to White/Caucasian subjects.[27] This is consistent with observations from clinical trials that Japanese patients tend to have higher exposure than their North American or European counterparts.[16] This pharmacokinetic difference provides a compelling explanation for the heightened hepatotoxicity signal observed specifically in Japanese clinical trials.[8] The systematically higher drug exposure in this population likely results in higher and more sustained concentrations within the liver, increasing the probability of exceeding a toxicity threshold and manifesting as clinically significant liver enzyme elevations. This finding directly connects population-specific pharmacokinetics to population-specific safety signals and helps to rationalize the divergent regulatory decisions made in different global regions.
• Other Factors: Other patient characteristics such as age and gender have also been identified as statistically significant covariates in PopPK models.[27] Female subjects are estimated to have a 30% higher AUC compared to male subjects.[8] However, this difference in exposure is not considered to be of sufficient clinical relevance to necessitate a dose adjustment based on gender.[8]

Clinical Efficacy and Therapeutic Application

The clinical value of Asunaprevir is defined by its efficacy in achieving a sustained virologic response (SVR), considered a cure for hepatitis C, when used as part of a combination antiviral regimen. Its application is targeted toward specific HCV genotypes and patient populations.

Approved Indications

Asunaprevir is indicated for the treatment of chronic hepatitis C (CHC) in adult patients with compensated liver disease, which may include cirrhosis.[1] Its use is strictly limited to combination therapy with other antiviral agents; it must not be administered as monotherapy due to the high likelihood of developing viral resistance.[25]

The specific approved regimens vary by viral genotype:

• HCV Genotype 1b: The primary indication for Asunaprevir is in a dual, all-oral regimen with the NS5A inhibitor daclatasvir.[1]
• HCV Genotype 1 or 4: For these genotypes, Asunaprevir is indicated as part of a quadruple therapy regimen that includes daclatasvir, peginterferon alfa, and ribavirin.[25]

Treatment with Asunaprevir-containing regimens should be initiated and monitored by a physician with experience in the management of chronic hepatitis C.[25]

Efficacy in Pivotal Clinical Trials

The efficacy of Asunaprevir has been established in a series of pivotal Phase II and Phase III clinical trials, which demonstrated high rates of SVR, particularly with interferon-free regimens. The data from these key trials are summarized in Table 2.

• Interferon-Free Regimens: The landmark HALLMARK-DUAL trial (NCT01581203) evaluated the all-oral combination of Asunaprevir and daclatasvir administered for 24 weeks.[30] This regimen proved highly effective in patients with HCV genotype 1b, achieving SVR at 12 weeks post-treatment (SVR12) rates between 80% and 90%.[4] Importantly, this high level of efficacy was observed across different patient populations, including those who were treatment-naïve and those who had previously failed to respond to interferon-based therapy ("null responders").[4] The regimen's effectiveness was also maintained in the difficult-to-treat population of patients with compensated cirrhosis.[31]
• Interferon-Based Regimens: In the HALLMARK-QUAD trial (NCT01573351), Asunaprevir was studied as part of a quadruple regimen with daclatasvir, peginterferon alfa, and ribavirin in patients with genotype 1 who were prior null or partial responders to interferon therapy.[25] This regimen also yielded high SVR rates, providing an effective option for this patient group.[25]
• Triple-DAA Regimens: Further studies, such as the UNITY trials (e.g., NCT01973049, NCT02123654), explored all-oral, interferon-free triple-DAA combinations.[30] A Phase 2a study of Asunaprevir, daclatasvir, and the NS5B polymerase inhibitor beclabuvir (formerly BMS-791325) reported an SVR12 rate of 92% in treatment-naïve patients with genotype 1, demonstrating the potential for even higher efficacy with multi-targeted DAA regimens.[33]
• Influence of Baseline Resistance: A critical factor that modulates the efficacy of Asunaprevir-based regimens is the presence of pre-existing resistance-associated substitutions (RASs). While Asunaprevir itself is susceptible to NS3 RASs, the efficacy of its primary combination partner, daclatasvir, is significantly compromised by baseline RASs in the NS5A gene, particularly at amino acid positions L31 or Y93.[3] In patients harboring these specific NS5A RASs, the SVR rates for the daclatasvir/asunaprevir combination are substantially reduced.[9] This finding underscores the clinical importance of baseline resistance testing to identify patients most likely to benefit from this specific regimen.

The clinical success of Asunaprevir is therefore highly context-dependent, defined by a confluence of viral genotype, baseline resistance profile, and the specific partner drugs with which it is combined. Its efficacy is potent but narrow. The data clearly delineates a hierarchy of effectiveness: it is highly potent against genotype 1b, less so against genotype 1a, and demonstrates weak activity against genotypes 2 and 3.[1] Furthermore, its clinical success is critically dependent on the absence of baseline NS5A RASs that would compromise the activity of daclatasvir.[9] This illustrates that the "efficacy" of Asunaprevir cannot be considered in isolation; it is an emergent property of the entire therapeutic regimen and the specific virological and host context. This complexity helps to explain why its marketing approvals were often restricted to specific subtypes, such as genotype 1b in China [5], and why resistance testing is a key consideration for treatment optimization.

Comparative Efficacy Analysis

To contextualize its clinical value, the efficacy of Asunaprevir-based regimens has been compared, both directly and indirectly, to other standards of care for chronic hepatitis C.

• Versus Interferon-Based Therapies: The advent of Asunaprevir-containing regimens represented a major therapeutic advance over the previous standard of care, which consisted of peginterferon alfa and ribavirin (P/R). Network meta-analyses and matching-adjusted indirect comparisons have consistently shown that the dual therapy of daclatasvir and Asunaprevir (DCV+ASV) results in statistically superior SVR rates compared to P/R alone or P/R combined with first-generation protease inhibitors such as telaprevir and boceprevir.[35] In addition to superior efficacy, the DCV+ASV regimen was associated with a significantly more favorable safety profile, with markedly lower rates of adverse events.[35]
• Versus Other All-Oral DAA Regimens: The development of Asunaprevir-based regimens represents a critical "bridging" phase in the rapid evolution of HCV therapy. While revolutionary compared to the interferon era, it was quickly followed by other highly effective all-oral DAA combinations. An indirect, matching-adjusted comparison was conducted using data from Japanese Phase III trials in patients with genotype 1b infection without baseline NS5A RASs.[34] This analysis found that the DCV+ASV regimen was associated with SVR12 rates (99.3%) and rates of discontinuation due to adverse events (1.3%) that were statistically similar to those of the fixed-dose, single-tablet regimen of sofosbuvir/ledipasvir (100% SVR12; 0.0% discontinuation).[34] This positions DCV+ASV as a highly effective therapeutic option, comparable to other leading regimens, but within a very specific and carefully selected patient population. This historical placement is significant: Asunaprevir was a pioneer in proving the concept of an all-oral cure, but it was almost immediately matched or surpassed by newer agents that offered greater convenience (e.g., once-daily single tablet), broader pangenotypic coverage, and a more favorable safety profile. Its story is a microcosm of the extraordinarily rapid pace of therapeutic innovation in the field of HCV during the mid-2010s.

Table 2: Efficacy of Asunaprevir-Based Regimens in Pivotal Clinical Trials

Trial Identifier	Regimen	Duration	Patient Population (Genotype, History, Cirrhosis)	N	SVR12 Rate (%)	Key Finding/Comment	Source Snippet(s)
Phase 2a	DCV + ASV + BMS-791325	12 or 24 weeks	GT-1, Treatment-Naïve	66	92%	High SVR rate with an all-oral, interferon-free triple DAA regimen.	33
HALLMARK-DUAL (NCT01581203)	DCV + ASV	24 weeks	GT-1b, Naïve, Non-responder, or Ineligible/Intolerant	918	80-90%	High efficacy in a broad GT-1b population, including those with cirrhosis and prior treatment failure.	4
HALLMARK-QUAD (NCT01573351)	DCV + ASV + Peg-IFN/RBV	24 weeks	GT-1 or GT-4, Prior Null/Partial Responders	398	High	Effective salvage therapy for patients who failed prior interferon-based treatment.	25
Japanese Phase III	DCV + ASV	24 weeks	GT-1b, Ineligible/Intolerant or Non-responder	110	97%	Extremely high SVR rate in a real-world setting when patients with baseline NS5A RASs were excluded.	31
Korean Study (NCT02580474)	DCV + ASV	24 weeks	GT-1b, On Hemodialysis	21	76.1% (ITT) / 100% (PP)	High efficacy in patients with end-stage renal disease, demonstrating safety in this population.	37
Japanese Phase III (MAIC)	DCV + ASV	24 weeks	GT-1b, No baseline NS5A L31/Y93 RASs	252	99.3%	After adjustment, efficacy was similar to Sofosbuvir/Ledipasvir in this selected population.	34

Abbreviations: ASV, Asunaprevir; DCV, Daclatasvir; GT, Genotype; ITT, Intention-to-Treat; MAIC, Matching-Adjusted Indirect Comparison; N, Number of patients; Peg-IFN/RBV, Peginterferon alfa/Ribavirin; PP, Per-Protocol; RASs, Resistance-Associated Substitutions; SVR12, Sustained Virologic Response at 12 weeks post-treatment.

Safety, Tolerability, and Risk Management

While Asunaprevir-based regimens offer superior efficacy and general tolerability compared to older interferon-based therapies, their use is associated with a significant and specific safety concern—hepatotoxicity—which has profoundly shaped their clinical application and regulatory status.

Primary Safety Concern: Hepatotoxicity

The principal dose-limiting toxicity and primary safety concern associated with Asunaprevir is the potential for drug-induced liver injury.[25] Across the clinical development program, a clear safety signal of hepatotoxicity was identified, characterized by on-treatment elevations of serum liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST).[2] In some cases, these transaminase elevations were accompanied by increases in total bilirubin, with or without systemic symptoms like fever or eosinophilia.[8]

This hepatotoxicity signal was observed to be particularly prominent in Japanese subjects participating in clinical trials.[8] Subsequent exposure-response modeling confirmed this observation, identifying several risk factors for developing Grade 3 or 4 (severe or life-threatening) ALT and bilirubin elevations. The final models included Asian race, higher Asunaprevir drug exposure, and, in non-Asian subjects, lower body weight as significant predictors of increased risk.[9] The pattern of adverse events provides clear evidence of the drug's disposition and potential for organ-specific toxicity. The primary toxicity is localized to the liver, which directly correlates with its hepatotropic distribution and extensive hepatic metabolism. This establishes a direct link between the drug's pharmacokinetic profile—which concentrates it in the liver—and its primary safety liability.

The risk of hepatotoxicity was deemed sufficiently serious to become the defining feature of Asunaprevir's safety profile and the primary driver of its limited global uptake and divergent regulatory fate. While its efficacy was demonstrated to be comparable to contemporary DAAs in specific populations [34], its hepatotoxicity risk was a unique and significant liability. This risk was the central reason cited by Bristol-Myers Squibb for the withdrawal of the U.S. New Drug Application (NDA) for Asunaprevir in 2014.[8] In contrast, the risk-benefit assessment in Japan, where HCV genotype 1b is highly prevalent, led to its approval, but with the implementation of stringent risk management strategies.[1] This highlights a critical principle of drug regulation: the same clinical dataset can lead to different regulatory outcomes depending on regional epidemiology, the availability of therapeutic alternatives, and the local tolerance for risk.

As a result of this known risk, prescribing information in countries where Asunaprevir is approved includes strong warnings and mandates a rigorous monitoring plan. The Australian Product Information, for example, contains the following boxed warning [3]:

WARNING: POTENTIAL FOR HEPATOTOXICITY.

For patients receiving SUNVEPRA-containing regimens, frequent monitoring of liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and bilirubin is required until completion of therapy.

Common and Other Serious Adverse Events

Beyond the primary concern of hepatotoxicity, Asunaprevir-containing regimens are generally considered well-tolerated, especially when compared to the significant side-effect burden of interferon-based therapies.[4] In clinical trials, the most commonly reported adverse events were typically mild to moderate in severity. These include headache, fatigue, nausea, diarrhea, pruritus (itching), and insomnia.[2]

In quadruple therapy regimens that include peginterferon and ribavirin, patients may experience the well-documented side effects associated with those agents, such as hematologic effects (e.g., neutropenia, anemia) and psychiatric effects (e.g., depression).[5]

Contraindications and Precautions

The known risks associated with Asunaprevir have led to a specific set of contraindications and precautions to ensure its safe use in appropriate patient populations.

Contraindications:

• Hepatic Impairment: Due to the profound increase in drug exposure and associated risk of toxicity, Asunaprevir is strictly contraindicated in patients with moderate or severe hepatic impairment (defined as Child-Pugh class B or C) and in any patient with decompensated liver disease.[7]
• Drug Interactions: Asunaprevir is contraindicated for co-administration with drugs that are moderate or strong inducers or inhibitors of the CYP3A enzyme system, as this can lead to a loss of efficacy or increased toxicity, respectively. It is also contraindicated with certain substrates of the CYP2D6 enzyme for which elevated plasma concentrations are associated with serious adverse events, such as ventricular arrhythmias.[25]
• Hypersensitivity: The drug is contraindicated in patients with a known hypersensitivity to Asunaprevir or any of the components in its formulation.[25]
• Pregnancy (with Ribavirin): When Asunaprevir is used as part of a regimen containing ribavirin, all contraindications applicable to ribavirin, most notably pregnancy, apply to the entire regimen due to ribavirin's teratogenic effects.[25]

Precautions:

• Liver Function Monitoring: The most critical precaution is the need for regular and frequent monitoring of liver function tests (ALT, AST, and bilirubin) for all patients throughout the duration of therapy to detect potential hepatotoxicity early.[3]
• Drug Interactions: Caution is advised when co-administering Asunaprevir with substrates of CYP2D6 or the P-glycoprotein (P-gp) transporter that have a narrow therapeutic index, as Asunaprevir can increase their concentrations.[16] The contraindication with CYP2D6 substrates linked to ventricular arrhythmias hints at a potential for indirect cardiovascular risk. While the direct cardiotoxicity of its predecessor was successfully engineered out of the molecule, this contraindication reveals that a risk of cardiac harm via drug-drug interactions remains a clinical concern that must be actively managed.

Drug-Drug Interaction Profile

Asunaprevir has a complex drug-drug interaction (DDI) profile due to its involvement as a substrate and inhibitor of several key drug metabolizing enzymes and transporters. This necessitates careful review of concomitant medications to avoid clinically significant interactions that could compromise efficacy or increase the risk of adverse events.

Mechanistic Basis of Interactions

The potential for drug interactions with Asunaprevir stems from its relationship with multiple pharmacokinetic pathways:

• Substrate Pathways: Asunaprevir is a substrate of the cytochrome P450 enzyme CYP3A4, the efflux transporter P-glycoprotein (P-gp), and the hepatic uptake transporters OATP1B1 and OATP2B1.[1] This means that drugs that induce or inhibit these pathways can significantly alter the plasma and intracellular concentrations of Asunaprevir.
• Inhibitor Pathways: Asunaprevir itself acts as a moderate inhibitor of CYP2D6 and a mild inhibitor of P-gp.[16] Therefore, it has the potential to increase the concentrations of other drugs that are substrates of these pathways.

This dual role as both a victim and a perpetrator of interactions through multiple major pathways creates a complex web of potential DDIs. This complexity significantly restricts its practical use, particularly in patients with comorbidities who require polypharmacy. The extensive list of contraindications with common drug classes (e.g., certain antibiotics, antifungals, anticonvulsants, HIV protease inhibitors, and many cardiovascular and psychiatric medications) makes prescribing Asunaprevir a challenging clinical task.[25] A physician must not only manage the patient's HCV but also conduct a thorough medication reconciliation and potentially alter or discontinue established therapies for other conditions, a process that may not be feasible or safe. This illustrates that a drug's clinical utility is determined not just by its intrinsic efficacy and safety, but also by its "pharmacological compatibility" with other medications, a domain where Asunaprevir has significant limitations.

Interactions Affecting Asunaprevir Concentrations

The concentration of Asunaprevir can be significantly altered by co-administered drugs, primarily through the modulation of CYP3A4 and OATP transporters.

• CYP3A4 Inducers: Co-administration with drugs that are moderate or strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, and the herbal supplement St. John's Wort) can substantially increase the metabolism of Asunaprevir. This leads to lower plasma concentrations and a high risk of therapeutic failure due to loss of virologic suppression. The use of such agents with Asunaprevir is contraindicated.[1]
• CYP3A4 Inhibitors: Conversely, co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, and HIV protease inhibitors like ritonavir) can block the metabolism of Asunaprevir, leading to significantly elevated plasma concentrations. This increased exposure heightens the risk of adverse events, particularly dose-dependent hepatotoxicity. This combination is also contraindicated.[2]
• OATP Inhibitors: Because hepatic uptake is a critical step in Asunaprevir's disposition, inhibitors of OATP transporters (e.g., cyclosporine, rifampin) can strongly affect its plasma exposure and are generally not recommended for co-administration.[16]
• Acid-Reducing Agents: Antacids containing aluminum or magnesium can decrease the absorption of Asunaprevir, resulting in reduced serum concentrations and potentially decreased efficacy. Staggered administration may be required.[12]

Interactions Caused by Asunaprevir

Asunaprevir can alter the pharmacokinetics of other drugs by inhibiting their metabolic or transport pathways.

• CYP2D6 Substrates: As a moderate inhibitor of CYP2D6, Asunaprevir can increase the plasma concentrations of drugs that are primarily cleared by this enzyme. This interaction is of greatest concern for CYP2D6 substrates that have a narrow therapeutic index, where even a modest increase in exposure can lead to serious toxicity. Examples include certain antiarrhythmics (e.g., flecainide, propafenone) and antipsychotics (e.g., thioridazine). Co-administration with such drugs is contraindicated.[16]
• P-gp Substrates: As a mild inhibitor of the P-gp transporter, Asunaprevir can increase the absorption and decrease the clearance of P-gp substrates. A clinically relevant example is digoxin, where co-administration with Asunaprevir can lead to increased digoxin levels and a risk of toxicity. Careful monitoring of digoxin concentrations is required if these drugs must be used together.[16]

A summary of the most clinically significant drug-drug interactions is provided in Table 3.

Table 3: Clinically Significant Drug-Drug Interactions with Asunaprevir

Interacting Drug/Class	Mechanism of Interaction	Effect on Asunaprevir or Interacting Drug	Clinical Recommendation	Source Snippet(s)
CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin, St. John's Wort)	Induction of CYP3A4	Decreases Asunaprevir concentration, risk of therapeutic failure.	Contraindicated	2
CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin)	Inhibition of CYP3A4	Increases Asunaprevir concentration, risk of toxicity (hepatotoxicity).	Contraindicated	2
CYP2D6 Substrates with Narrow Therapeutic Index (e.g., Flecainide, Thioridazine)	Inhibition of CYP2D6 by Asunaprevir	Increases concentration of the substrate, risk of serious toxicity (e.g., arrhythmias).	Contraindicated	16
OATP1B1/2B1 Inhibitors (e.g., Cyclosporine, Rifampin)	Inhibition of hepatic uptake	Increases Asunaprevir plasma concentration.	Co-administration is not recommended.	16
P-gp Substrates (e.g., Digoxin, Dabigatran)	Inhibition of P-gp by Asunaprevir	Increases concentration of the substrate.	Use with caution; monitor substrate drug levels and for toxicity.	16
Antacids (e.g., Aluminum Hydroxide, Almasilate)	Decreased Absorption	Decreases Asunaprevir concentration, potential for reduced efficacy.	Avoid simultaneous administration.	12
Statins (e.g., Pravastatin, Rosuvastatin)	Inhibition of uptake/efflux transporters	May increase statin concentration, risk of myopathy.	Use with caution; consider dose reduction of statin.

Regulatory History and Global Market Status

The regulatory journey of Asunaprevir is a compelling narrative of scientific breakthrough, regional success, and global limitations, reflecting the complex interplay between clinical data, evolving standards of care, and differing regulatory philosophies.

Development and Approval Timeline

Asunaprevir was discovered and developed by Bristol-Myers Squibb as a second-generation HCV NS3/4A protease inhibitor.[11] Its clinical development culminated in its first global approval in Japan in July 2014.[1] This approval was a landmark event, as the combination of Asunaprevir (Sunvepra®) and daclatasvir (Daklinza®) constituted the world's first all-oral, interferon- and ribavirin-free regimen for the treatment of chronic HCV genotype 1 infection.[6]

Following its debut in Japan, Asunaprevir gained marketing authorization in several other countries, including Russia, where it is also marketed as Sunvepra®.[11] A significant approval came in 2017 from the China Food and Drug Administration (CFDA), again for the dual regimen with daclatasvir for genotype 1b infection, which is the most common genotype in China.[5] Health Canada also approved the drug in April 2016.[1]

Divergent Global Regulatory Outcomes

Despite its success in Asia and other regions, Asunaprevir's path to market was blocked in the United States and the European Union, highlighting a stark divergence in regulatory assessments.

• United States: Bristol-Myers Squibb submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Asunaprevir in combination with daclatasvir. However, during the review process, the significant signal for hepatotoxicity, particularly in certain patient populations, became a major point of concern. In light of this safety risk and the rapidly evolving therapeutic landscape with the emergence of alternative, safer DAAs, the company made the decision to withdraw the Asunaprevir NDA in 2014.[8] As a result, Asunaprevir is not approved for use in the United States.[5]
• European Union: Asunaprevir does not have a marketing authorization from the European Medicines Agency (EMA) for the treatment of adult patients with chronic hepatitis C. Its regulatory history with the EMA is unusual and noteworthy. The EMA's Paediatric Committee (PDCO) agreed to a Paediatric Investigation Plan (PIP) for Asunaprevir (as part of a combination therapy) in 2012, which was subsequently modified in 2015.[1] A PIP is a mandatory component of drug development in Europe, designed to ensure that the needs of pediatric populations are considered. The existence of an agreed PIP in the absence of an adult marketing authorization is a regulatory artifact. It suggests that a full marketing authorization application for adults was anticipated at one point but was likely halted or withdrawn by the sponsor, probably due to the same hepatotoxicity concerns that led to the U.S. NDA withdrawal, as well as the emergence of superior competitors. This leaves Asunaprevir in a state of regulatory limbo in Europe—never fully approved for its primary indication, but with a formal pediatric development plan on record.

The regulatory history of Asunaprevir serves as a case study in how the "race to cure" HCV created a rapidly shifting landscape where the standards for approvability, especially concerning safety, were constantly being redefined. Asunaprevir was a pioneer, part of the first wave of all-oral cures, and its 2014 approval in Japan was a genuine breakthrough.[40] However, by the time its application was under review in the U.S., the clinical and regulatory environment had already been transformed by the approval of other highly effective and safer DAA regimens, such as those based on sofosbuvir. The FDA's risk-benefit calculation for Asunaprevir was therefore made not in a vacuum, but in the context of these imminent and superior alternatives. Its hepatotoxicity, a risk that might have been deemed acceptable a year earlier, was likely viewed as untenable by late 2014, leading directly to the NDA withdrawal. Asunaprevir was, in effect, a victim of the rapid progress it had helped to initiate.

Commercialization and Market Withdrawal

Even in markets where Asunaprevir received regulatory approval, its commercial lifecycle has been challenging. This is exemplified by its trajectory in Canada. Following its approval by Health Canada in April 2016, its commercialization was officially cancelled just over a year later, in October 2017.[1] This rapid withdrawal from the market, despite being an approved product, strongly suggests that it faced intense competitive pressure from newer DAA regimens that offered pangenotypic coverage, simpler once-daily dosing, and a more favorable safety profile. This commercial outcome underscores that regulatory approval is only one hurdle; long-term market viability depends on a drug's ability to remain competitive within a dynamic therapeutic class.

Conclusion and Future Directions

The story of Asunaprevir is a multifaceted narrative of innovation, clinical success, significant limitations, and an evolving legacy that now extends beyond its original indication. It stands as a pivotal, albeit flawed, molecule in the history of antiviral therapy.

Synthesis of Asunaprevir's Role and Legacy

Asunaprevir's development represents a clear triumph of rational drug design. Medicinal chemists at Bristol-Myers Squibb successfully identified and engineered out the specific cardiovascular toxicities that had halted the development of its predecessor, BMS-605339, delivering a molecule with a clean cardiac safety profile.[6] This achievement alone is a significant scientific success.

Clinically, Asunaprevir's legacy is secured by its role as a core component of the first all-oral, interferon-free regimens to demonstrate a cure for chronic hepatitis C.[4] The dual therapy of Asunaprevir and daclatasvir provided the crucial proof-of-concept that HCV could be eradicated without the severe, debilitating side effects of interferon, fundamentally altering the treatment landscape and raising patient and physician expectations for what was possible.

However, this legacy of success is inextricably linked to its significant limitations. The prominent risk of hepatotoxicity, which exhibited variability across different ethnic populations, became its Achilles' heel, leading to its failure to gain approval in key Western markets.[8] Furthermore, its low barrier to resistance and its narrow spectrum of potent genotypic activity confined its utility, making it a less robust option compared to the pangenotypic regimens that followed.[4]

This complex profile makes Asunaprevir a perfect illustration of a "successful failure" in drug development. It "failed" to achieve the blockbuster status or widespread global approval of its contemporaries. Yet, it was profoundly "successful" in multiple respects. It provided the clinical validation for the entire field of interferon-free DAA combinations; it offered a curative and life-saving therapy in specific markets like Japan and China where it met a major unmet medical need; and its well-characterized pharmacology has endowed it with a new life as a valuable research tool. Its ultimate value, therefore, extends far beyond its limited commercial footprint.

Emerging Research and Non-HCV Applications

While its use in treating HCV has been largely superseded by newer agents, the unique properties of Asunaprevir have led to its exploration in cutting-edge areas of biomedical research, giving the molecule a second life beyond virology.

• Chemogenetic Control of CRISPR-Cas9 Gene Editing: A significant and innovative application of Asunaprevir is its use as a molecular switch to control the activity of the CRISPR-Cas9 gene editing system. In a technique known as small molecule-assisted shut-off (SMASh), the Cas9 nuclease is fused to a peptide containing the NS3 protease cleavage site and a degradation tag (a "degron").[22] In the absence of Asunaprevir, the NS3 protease domain self-cleaves, removing the degron and allowing the Cas9 protein to be stable and active. When Asunaprevir is introduced, it inhibits the protease, preventing the removal of the degron. This targets the entire fusion protein for degradation via the proteasome and autophagolysosome pathways, effectively shutting down Cas9 activity.[22] This provides a potent, tunable, and reversible "off-switch" for gene editing, which could be a critical safety feature for future therapeutic applications of CRISPR technology.[22]
• Potential Antiviral Activity against SARS-CoV-2: In the search for existing drugs that could be repurposed to treat COVID-19, Asunaprevir has emerged as a candidate of interest. Preclinical, in vitro studies have shown that Asunaprevir can inhibit the propagation of SARS-CoV-2 in cell culture.[22] It was observed to significantly decrease the release of infectious virions from infected cells and may act at the early binding or entry stage of the viral lifecycle.[43] While this research is still in its early stages and has not been validated in clinical settings, it suggests that Asunaprevir may possess broader antiviral properties that warrant further investigation, potentially as a component of future combination therapies for other viral diseases.

In conclusion, Asunaprevir's journey from a targeted HCV therapeutic to a sophisticated tool for controlling gene editing and a potential candidate for combatting new viral threats demonstrates the enduring value that can be derived from well-characterized small molecules. Its story is a powerful reminder that the legacy of a drug is not solely defined by its commercial success, but also by its impact on scientific progress and its potential to enable future medical breakthroughs.

Works cited

1. Asunaprevir | C35H46ClN5O9S | CID 16076883 - PubChem, accessed September 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Asunaprevir
2. What is Asunaprevir used for? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-is-asunaprevir-used-for
3. AU_SUNVEPRA_PI_v0-3_11 Mar, accessed September 6, 2025, https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214-pi.pdf
4. Asunaprevir, a protease inhibitor for the treatment of hepatitis C ..., accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4079632/
5. China FDA Approves Country's First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir) - Bristol Myers Squibb - Press Releases, accessed September 6, 2025, https://news.bms.com/news/details/2017/China-FDA-Approves-Countrys-First-All-Oral-Regimen-for-Chronic-Hepatitis-C-Daklinza-daclatasvir-in-Combination-with-Sunvepra-asunaprevir/default.aspx
6. The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious ..., accessed September 6, 2025, https://pubs.acs.org/doi/10.1021/jm500297k
7. Asunaprevir, a protease inhibitor for the treatment of hepatitis C inf - Dove Medical Press, accessed September 6, 2025, https://www.dovepress.com/asunaprevir-a-protease-inhibitor-for-the-treatment-of-hepatitis-c-infe-peer-reviewed-fulltext-article-TCRM
8. 206843Orig1s000 - FDA - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206843Orig1s000SumR.pdf
9. Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6590348/
10. Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease - ACS Publications, accessed September 6, 2025, https://pubs.acs.org/doi/10.1021/cb5006118
11. Asunaprevir - Wikipedia, accessed September 6, 2025, https://en.wikipedia.org/wiki/Asunaprevir
12. Asunaprevir: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 6, 2025, https://go.drugbank.com/drugs/DB11586
13. en.wikipedia.org, accessed September 6, 2025, [https://en.wikipedia.org/wiki/Asunaprevir#:~:text=Asunaprevir%20(formerly%20BMS%2D650032%2C,the%20treatment%20of%20hepatitis%20C.](https://www.google.com/url?q=https://en.wikipedia.org/wiki/Asunaprevir%23:~:text%3DAsunaprevir%2520(formerly%2520BMS%252D650032%252C,the%2520treatment%2520of%2520hepatitis%2520C.&sa=D&source=editors&ust=1757160089539763&usg=AOvVaw1dBtv77hIwzpCqmWiCm8Ms)
14. The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032) - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7123690/
15. Asunaprevir 98% | CAS: 630420-16-5 | AChemBlock, accessed September 6, 2025, https://www.achemblock.com/asunaprevir.html
16. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics ..., accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/26177803/
17. Asunaprevir | CAS 630420-16-5 | SCBT - Santa Cruz Biotechnology, accessed September 6, 2025, https://www.scbt.com/p/asunaprevir-630420-16-5
18. Asunaprevir, 630420-16-5, 98 (HPLC) Sigma-Aldrich, accessed September 6, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml3812
19. The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection | Journal of Medicinal Chemistry - ACS Publications, accessed September 6, 2025, https://pubs.acs.org/doi/abs/10.1021/jm500297k
20. The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection | Request PDF - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/260377266_The_Discovery_of_Asunaprevir_BMS-650032_An_Orally_Efficacious_NS3_Protease_Inhibitor_for_the_Treatment_of_Hepatitis_C_Virus_Infection
21. Asunaprevir (BMS 650032, CAS Number: 630420-16-5) | Cayman Chemical, accessed September 6, 2025, https://www.caymanchem.com/product/20835/asunaprevir
22. Asunaprevir | Hepatitis Viruses - Tocris Bioscience, accessed September 6, 2025, https://www.tocris.com/products/asunaprevir_7755
23. What is the mechanism of Asunaprevir? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-asunaprevir
24. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032) | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 6, 2025, https://journals.asm.org/doi/10.1128/aac.01186-12
25. asunaprevir, accessed September 6, 2025, https://pdf.hres.ca/dpd_pm/00037935.PDF
26. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/271596856_Preclinical_Pharmacokinetics_and_In_Vitro_Metabolism_of_Asunaprevir_BMS-650032_a_Potent_Hepatitis_C_Virus_NS3_Protease_Inhibitor
27. Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/29589331/
28. Asunaprevir for hepatitis C: a safety evaluation - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/26329454/
29. B.C. PharmaCare Drug Information Sheet for asunaprevir (SUNVEPRA) - Gov.bc.ca, accessed September 6, 2025, https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/asunaprevir-3382-info.pdf
30. Asunaprevir Completed Phase 3 Trials for Hepatitis C Infections Treatment - DrugBank, accessed September 6, 2025, https://go.drugbank.com/drugs/DB11586/clinical_trials?conditions=DBCOND0072126&phase=3&purpose=treatment&status=completed
31. The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5753689/
32. Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile | PLOS One - Research journals, accessed September 6, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141660
33. (PDF) Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/258252238_Efficacy_of_an_Interferon-_and_Ribavirin-Free_Regimen_of_Daclatasvir_Asunaprevir_and_BMS-791325_in_Treatment-Naive_Patients_With_HCV_Genotype_1_Infection
34. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C ..., accessed September 6, 2025, https://becarispublishing.com/doi/10.2217/cer.15.69
35. Comparative efficacy and safety of daclatasvir/asunaprevir versus ..., accessed September 6, 2025, https://becarispublishing.com/doi/abs/10.2217/cer.15.33
36. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection - Becaris Publishing, accessed September 6, 2025, https://becarispublishing.com/doi/10.2217/cer.15.33
37. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis - Gut and Liver, accessed September 6, 2025, https://www.gutnliver.org/journal/view.html?doi=10.5009/gnl18240
38. What are the side effects of Asunaprevir? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-asunaprevir
39. Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 6, 2025, https://journals.asm.org/doi/10.1128/aac.01603-15
40. Daclatasvir + asunaprevir: first global approval - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/25117197/
41. European Medicines Agency decision P/0002/2015 of 15 ... - EMA, accessed September 6, 2025, https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2015-ema-decision-15-january-2015-15-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-daclatasvir-dihydrochloride-asunaprevir-1ar12bs-8-cyclohexyl-n_en.pdf
42. EMEA-001190-PIP01-11 - paediatric investigation plan - European Medicines Agency, accessed September 6, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001190-pip01-11
43. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8490202/